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Randomized controlled expressive writing
pilot in individuals with Parkinson’s disease
and their caregivers
Therese Verkerke Cash1,2* and Sarah K. Lageman1,3
Abstract
Background: Individuals with Parkinson’s disease (PD) and their caregivers are at risk for emotional distress and
hypercortisolism. Expressive writing is an effective complementary intervention to ameliorate the psychological
and physiological effects of chronic illness. This pilot study aimed to evaluate feasibility and preliminary effectiveness
of an expressive writing intervention for individuals with PD and their caregivers.
Methods: Individuals with PD (N = 27) and their caregivers (N = 14) were randomly assigned to expressive (N = 15
patients, eight caregivers) or neutral (N = 12 patients, six caregivers) writing conditions. Cortisol awakening response
(CAR), non-motor functioning, quality of life, and performance on tests of cognitive functioning were assessed at
baseline, immediate post, 4-month, and 10-month post intervention.
Results: Attrition was a challenge as eight patients (29.62 %) and four caregivers (28.57 %) chose to discontinue before
beginning the intervention or were lost to follow up prior to completing the intervention or the first follow up
visit. Significant reduction in anxiety, marginally significant improvement in depression and caregiver burden, and
significant improvements in performance on tests of learning and memory were observed, but these changes did not
differ by writing condition. CAR significantly differed over time between patients and caregivers and writing conditions.
Conclusions: Some evidence for the feasibility and effectiveness of writing to alleviate hypercortisolism was
demonstrated in a small sample of PD patients; however, relatively high attrition rates and the lack of difference between
expressive and neutral writing conditions on emotional and neurocognitive outcomes suggests expressive writing
procedure modifications may be needed to obtain optimal results for this population.
Trial registration: ClinicalTrials.gov, NCT02217735, Study Start Date: August 30, 2011.
Keywords: Expressive writing, Salivary cortisol, Parkinson’s disease, Quality of life, Caregiver
Background
Expressive writing is a brief psychosocial intervention
with known emotional and physical health benefits
[16]. The classic expressive writing paradigm [37] in-
volves 3, 20 min writing sessions within a 2 week
period, during which participants are encouraged to
openly express their thoughts and feelings about a
stressful or traumatic real life event. Research supports
the use of expressive writing as an adjunctive therapy in
chronically ill populations [2]. Specifically, expressive writ-
ing has led to both mental and physical health gains in pa-
tients diagnosed with fibromyalgia [5], asthma and
rheumatoid arthritis [47], and cancer [54]. Additionally, a
form of expressive writing has been successfully employed
to reduce depressed mood in chronic pain patients [19],
to decrease cortisol reactivity and enhance post-traumatic
growth in PTSD patients [48], and to moderate autonomic
response in individuals with elevated blood pressure [35].
Individuals with Parkinson’s disease (PD) and their
caregivers are at risk for increased emotional distress
[1], cognitive declines [51], and elevated cortisol levels
[10, 12, 22]. While research on psychosocial treatment
options in PD are limited, a recent randomized clinical
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trial compared cognitive-behavioral therapy (CBT) to usual
care in a sample of individuals with PD and found improve-
ments in symptoms of depression, anxiety, quality of life
(QOL), coping, and PD symptom ratings for the CBTgroup
only, and these benefits were sustained at a 14-week follow
up assessment [13]. Caregivers of individuals with PD also
showed improvement on measures of caregiver strain and
subjective burden after receiving 12–14 sessions of CBT
compared to those in a no-treatment control group [44].
While CBT seems to be effective, many individuals may
be unwilling or unable to partake in weeks of therapy to re-
duce physical and emotional stress. Therefore, it may be
fruitful to consider briefer, cost effective alternatives. Ex-
pressive writing is one such alternative therapy with strong
empirical support in other related groups that may en-
hance physical and emotional functioning in patients and
caregivers coping with PD. It has also been found to aug-
ment working memory through reductions in avoidant and
intrusive thoughts [28]. Expressive writing has been theo-
rized to operate according to some of the same principles
as CBT (i.e., exposure, cognitive restructuring) [45], and it
has been demonstrated to consistently result in small to
moderate effect sizes [16, 46].
The use of expressive writing in PD may be particularly
well-suited to this population due to findings that both
PD and caregiving are associated with abnormalities in
stress hormone levels. One study [22] found evidence of
sustained hypercortisolism in PD patients compared to
normal controls. More recent studies have linked high
cortisol levels to behavioral problems in PD [12] and ele-
vated cortisol levels upon awakening in individuals caring
for dementia patients [10]. Negative consequences of
hypercortisolism include detriments to multiple organ sys-
tems and declines in cognition and memory systems [22].
Therefore, efforts to reduce cortisol levels through psy-
chosocial interventions are likely to have important impli-
cations for overall physical and emotional health in
individuals with PD and their caregivers. For example, one
recent study showed reductions in cortisol concentration
in a sample of PD patients following both an active thera-
peutic massage intervention and a control resting to music
condition [50]. The cortisol awakening response (CAR),
captured by assessing cortisol concentrations at intervals
after waking, is a metric of HPA axis activation that is asso-
ciated with psychosocial functioning [8] and has been
shown to be a valuable measure for assessing hyper- and
hypocortisolemic traits in patients with depression and
chronic fatigue [24].
Expressive writing is a novel psychosocial interven-
tion that may effectively target non-motor symptoms
and emotional and physical stress and enhance QOL
for patients and caregivers coping with PD. Based on
the existing literature, we anticipate that an expressive
writing intervention will lead to improvements in self-
reported emotional functioning and cognitive perform-
ance, and reductions in objective stress hormone levels
among individuals with PD and their caregivers and that
these benefits will be sustained at 4-month and 10-month
follow up evaluations. Primary outcomes of this study in-
clude self-reported anxiety, depression, apathy, non-motor
symptoms (PD patients only), health-related QOL (PD pa-
tients only), overall QOL, caregiver burden (caregivers
only), performance on cognitive tests assessing processing
speed, auditory attention, learning, memory, mental flexi-
bility, and working memory, and CAR.
Methods
Participants
In this pilot study, individuals with PD (N = 27) and their
caregivers (N = 14) were recruited and randomly assigned
to expressive (N= 15 patients, eight caregivers) or neutral
(N= 12 patients, 6 caregivers) writing conditions. Partici-
pants were patients or family members of patients re-
cruited from a movement disorders specialty clinic in the
southeastern United States during routine clinical exams
or through the clinic’s email listserv. Inclusion criteria for
patients included a neurologist-confirmed diagnosis of PD
and adult age (18 or older). Adult age caregivers were only
able to participate if the individual with PD that they care
for participated in the study. Patients were excluded if
their clinical records showed evidence of a severe, un-
treated mental illness and/or a dementia diagnosis. Study
activities were completed from August 2011 until June
2013. Recruitment for the study was ended in order to
conclude data collection within an approximately 2 year
timeframe. Initially, 66 individuals with PD were identified
as meeting inclusion criteria for this study, and all were
contacted by phone or in person to discuss participation.
Of those initially identified as eligible, 39 opted not to par-
ticipate, citing travel distance to the clinic, other time
commitments, or a lack of interest as their reasons for de-
clining. (Please see Additional file 1: Figure S1 in supple-
mental materials for CONSORT flow diagram of study
recruitment and retention.) No significant differences on
demographic characteristics were noted between those
who elected to participate and those who declined. Mean
age of the entire sample was 67.15 (SD = 7.63). The sample
was equally divided among males and females (50 %
female). The average level of education was 16 years. All
participants identified as White and not of Hispanic
origin. No significant differences on these sample charac-
teristics were found across the two writing conditions or
between patients and caregivers. This study was com-
pleted with adequate understanding and written consent
of the participants and with the ethical approval of the
Virginia Commonwealth University Institutional Review
Board. Participants were given the option to participate
with or without providing salivary cortisol samples.
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Design
This study employed a 2 Writing Condition (expressive
writing, neutral writing) x 2 Participant Status (Patients,
Caregivers) x 4 Time (Baseline, Immediate Post, 4
Month, 10 Month) mixed design. Participants were ran-
domly assigned to an experimental (expressive writing)
or a control (neutral writing) condition (see instructions
below). Patients and caregivers who participated in the
study together were assigned to the same writing condi-
tion but completed the writing exercises independently.
The decision to assign patients and caregivers to the
same writing condition was based on two assumptions.
First, we predicted that patients and caregivers partici-
pating together would be likely to discuss the interven-
tion and that assigning them to different conditions
might dilute the effects of the writing condition to which
they were assigned. Second, we assumed that effects of
the intervention on one participant in the dyad might
affect the other such that assigning participants within a
dyad to different writing conditions could have added
additional error variability for which we were unable to
control in a small pilot study. Randomization order was
generated using an online randomization generator
(http://www.randomizer.org/), and participants were
assigned to condition in the order of study enrollment.
The allocation of dyads compared to non-dyads did not
significantly differ across the two writing conditions, F(1,
37) = 2.24, p = .143, indicating that randomization was
successful. Efforts to reduce experimenter bias included
distributing participants’ writing instructions in a sealed
folder so that the experimenter was unaware of the writ-
ing condition and using multiple research assistants who
were unaware of participants’ study condition to admin-
ister baseline and follow up assessments.
Procedure
The study intervention involved patient and caregiver
completion of 3, 20-minute writing sessions at an inter-
disciplinary movement disorders clinic in a private room
or at home for individuals who lived greater than 1 h
away from the center. The writing instructions [37]
given to the expressive and neutral conditions at each of
the three writing sessions are below:
Instructions for expressive writing condition
For the next 3 days, I would like you to write your very
deepest thoughts and feelings about the most traumatic ex-
perience of your entire life or an extremely important emo-
tional issue that has affected you and your life. In your
writing, I’d like you to really let go and explore your dee-
pest emotions and thoughts. You might tie your topic to
your relationships with others, including parents, lovers,
friends or relatives; to your past, your present or your fu-
ture; or to who you have been, who you would like to be or
who you are now. You may write about the same general
issues or experiences on all days of writing or about differ-
ent topics each day. All of your writing will be completely
confidential. Don’t worry about spelling, grammar or sen-
tence structure. The only rule is that once you begin writ-
ing, you continue until the time is up.
Instructions for neutral writing condition
What I would like you to write about over the next 3 days
is how you use your time. In your writing, I want you to be
as objective as possible. I am not interested in your emo-
tions or opinions. Rather I want you to try to be completely
objective. Feel free to be as detailed as possible. In today’s
writing, I want you to describe what you did yesterday
from the time you got up until the time you went to bed.
For example, you might start when your alarm went off
and you got out of bed. You could include the things you
ate, where you went, which buildings or objects you passed
by as you walked from place to place. The most important
thing in your writing, however, is for you to describe your
days as accurately and as objectively as possible. All of
your writing will be completely confidential. Don’t worry
about spelling, grammar or sentence structure. The only
rule is that once you begin writing, you continue until the
time is up.
Accommodations were made to ensure that participants
at all levels of motor functioning were able to participate.
Participants (N = 6) who were unable to handwrite all se-
lected to type into a secure word-processing document on
a computer, and these individuals were equally divided
across the two writing conditions.
Outcome measures
Outcome measures consisted of self-reported emotional
functioning, QOL, performance on a brief battery of cog-
nitive tests, and stress hormone levels. These outcomes
were assessed prior to the first writing session (baseline),
shortly after the third writing session (immediate post,
mean follow up = 5.00 days), and at four (4-month follow
up, mean follow up = 123.86 days) and 10 month follow-
up (10-month follow up, mean follow up = 308.61 days)
appointments. Self-reported outcomes were collected,
managed, and stored in a secure web-based database (Re-
search Electronic Data Capture (REDCap) [21]. The stress
hormone levels were self-collected at home and then
hand delivered for freezer storage. Specific measures
and details of the stress hormone collection are de-
scribed in detail below.
Self-report measures
A compilation of validated self-report questionnaires were
used to assess various aspects of emotional functioning
among the patient and caregiver participants and estab-
lished clinical guidelines were used to interpret all scores.
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Cronbach’s alpha was calculated for each measure within
the full study sample at baseline to assess internal reliabil-
ity of these measures in our sample, with the following
rule of thumb used for interpretation of alpha values: α ≥
0.9 Excellent, 0.9 > α ≥ 0.8 Good, 0.8 > α ≥ 0.7 Acceptable,
0.7 > α ≥ 0.6 Questionable, 0.6 > α ≥ 0.5 Poor, 0.5 < α Un-
acceptable [18]. All self-report measures were found to
have at least acceptable internal consistency in our sample.
All participants completed the Multidimensional Anx-
iety Questionnaire (MAQ; [41], a 40-item self-report in-
strument that captures anxiety within four domains
(Physiological-Panic, Social Phobia, Worry-Fears, and
Negative Affectivity) as well as an overall Total Score. The
MAQ was selected to allow for differentiation of physical,
cognitive, and emotional anxiety symptoms, given poten-
tial for elevated physical symptoms associated with PD.
Good reliability and validity have been demonstrated for
the MAQ, and separate norms are available for commu-
nity adults and college students [41]. Community adult
norms were used within this study, and established clinical
cutoffs were relied upon for interpretation of scores.
Cronbach’s alpha for the MAQ was calculated in our sam-
ple with, α = .91, indicating excellent internal consistency.
The Beck Depression Inventory-II (BDI-II; [3], a 21-item
self-report questionnaire was used to capture the severity
of depression symptoms for patients and caregivers.
Strong psychometric properties have been established for
the BDI-II, and it has been demonstrated to be a reliable
measure of depression in older adult samples [17]. Cron-
bach’s alpha for the BDI was calculated in our sample
with, α = .83, indicating good internal consistency.
The Apathy Scale (AS; [49] is a 14-item scale that was
developed and validated to screen for apathy symptoms in
individuals with PD. For caregivers, a modified version of
item three was administered, which directed caregivers to
consider their current condition, including social, financial,
familial, physical, or emotional aspects of their functioning.
Cronbach’s alpha for the AS was calculated in our sample
with, α = .74, indicating acceptable internal consistency.
All participants also completed the Linear Analogue
Self Assessment (LASA; [32], which assesses dimensions
of physical, emotional, spiritual, intellectual, and overall
QOL using single items. A recent needs assessment sur-
vey used this instrument to capture overall QOL in a
sample of high functioning PD patients [31]. Cronbach’s
alpha was not calculated for this scale because interpret-
ation is done at the single-item level.
Daily cognitive functioning was measured in both pa-
tients and caregivers with the Everyday Cognition scale
(ECOG; [14]), which provides a total score as well as six
subscales measuring memory, language, visuospatial abil-
ities, and planning, organization, and divided attention sub-
domains of executive functioning. This scale was validated
in a large sample of older adults whose cognitive function
ranged from healthy to demented [14]. Cronbach’s alpha
for the ECOG total was calculated in our sample with,
α = .98, indicating excellent internal consistency.
Patient specific measures included the Parkinson’s Dis-
ease Non-Motor Symptom Questionnaire (PD-NMS; [7],
a 30-item questionnaire developed to assess the fre-
quency of common non-motor symptoms in individuals
with PD, and the Parkinson’s Disease Questionnaire-39
(PDQ-39; [27], a 39-item self-report questionnaire which
evaluates the impact of PD on QOL across eight do-
mains, including Bodily Discomfort, Mobility, Activities
of Daily Living, Emotional Well Being, Communication,
Cognitive Impairment, Stigma, and Social Support. Both
the PD-NMS and the PDQ-39 have been well validated in
PD samples to capture non-motor symptomatology and
health-related QOL, respectively. Cronbach’s alpha for the
PD-NMS was calculated in our sample with, α = .78, indi-
cating acceptable internal consistency.
Finally, caregiver burden was assessed using the 12-item
short form of the Zarit Burden Inventory (ZBI; [4], which
assesses the impact of caregiving on the caregiver’s emo-
tional and physical health, as well as their ability to engage
in social activities. Adequate psychometric properties of
the short-form ZBI were demonstrated in a large sample
of caregivers of cognitively impaired older adults and are
likely to generalize to other caregivers of community
dwelling older adults. Cronbach’s alpha for the ZBI was
calculated in our sample with, α = .76, indicating accept-
able internal consistency.
Cognitive performance measures
Patient and caregiver participants completed a brief bat-
tery of neurocognitive measures including tests assessing
processing speed and mental flexibility (Trailmaking Tests
A & B [23, 40], auditory attention and working memory
(Digit Span (DS) and Letter Number Sequencing (LNS)
[11, 53]; Auditory Consonant Trigrams (ACT) [6, 38] and
verbal learning and memory (California Verbal Learning
Test – II (CVLT) [11]).
Writing theme code book
Writing samples from the expressive writing condition
were reviewed, coded, and tested for inter-rater reliability
in order to be able to optimally categorize the writing
topics. It was initially hypothesized that a majority of the
participants in the expressive condition would select PD
diagnosis as their writing topic, given salience of PD as a
major medical illness in their lives. However, when the
writing samples were reviewed, PD diagnosis was selected
as a writing topic by only one patient out of 11 and none
of the caregivers. Because the number of participants that
selected PD diagnosis as their writing topic was not suffi-
cient, a wider range of writing topics was taken into con-
sideration. A codebook of categorical writing topics was
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established by the research team. Two researchers (TVC
and SKL) independently rated the writing topics in order
to establish inter-rater reliability of the codebook categor-
ies, which was measured by Cohen’s kappa coefficient.
Cohen’s kappa coefficient (κ = 0.93) indicated strong inter-
rater reliability for the codebook categories.
Stress hormone measurement
The CAR has been shown to be a valuable measure for
assessing hyper- and hypocortisolemic traits in patients
with depression and chronic fatigue [24]. Specifically,
overall waking cortisol level, known as AUCt, can provide
reliable trait-level information about the activity level of
the HPA axis [24]. In line with established reliability cri-
teria [24], AUCt levels were assessed using saliva samples
collected on 2 weekday mornings immediately after wak-
ing, as well as 30, 45 and 60 min after the waking time at
each of the four timepoints (Baseline, Immediate Post, 4-
Month, 10-Month). A total of 32 samples over the course
of the study (four samples on eight different mornings)
were self-collected by participants at home using a saliv-
ette device. Participants were asked to record sample col-
lection times in a provided log as well as on the sample
tubes to ensure that data was collected at the correct
times. Subjects were asked to store the salivettes in the
freezer and to deliver them to our clinic immediately after
collecting the last consecutive sample. In the center-
associated laboratory, the saliva samples were centrifuged
and stored at −20°C until analyzed using salivary cortisol
analysis performed by the Center for Clinical & Transla-
tion Research’s Clinical Research Services Unit Laboratory
utilizing a sandwich immunoassay methodology supplied
by Salimetrics, LLC. To our knowledge, the CAR has not
been evaluated previously among individuals with PD or
their caregivers. In one prior study [39], the CAR was cap-
tured in a sample of healthy older adults, and levels
peaked at 30 min post awakening, with an average of
.91 μg/dL at that time point. Assessment of the CAR
among Alzheimer’s patients and their caregivers revealed
elevations at 30 min post awakening, with average levels
of 1.20 μg/dL for caregivers and 1.30 μg/dL for patients
[52]. For analyses in this study, salivary cortisol levels at
waking, and 30, 45, and 60 min post waking across the
two collection days were averaged at each study time
point, and these values are presented in Table 1, with
higher values indicating greater cortisol reactivity.
Results
Feasibility
From an initial sample of eligible individuals with PD
(N = 27) and caregivers (N = 14) who consented to par-
ticipate in the study, 15 patients and eight caregivers
were randomly assigned to the expressive writing con-
dition and 12 patients and six caregivers were assigned
to the neutral writing condition. Eight patients (29.62 %;
four randomized to expressive writing and four random-
ized to neutral writing) and four caregivers (28.57 %; two
randomized to expressive writing and two randomized to
neutral writing) chose to discontinue before beginning the
intervention or were lost to follow up prior to completing
the intervention or the first follow up visit. There were no
significant differences in attrition between the two condi-
tions, and participants cited not wanting to disclose per-
sonal information, travel distance to the clinic for multiple
follow up appointments, and new medical symptoms un-
related to the study intervention as reasons for discontinu-
ing. The final sample included in the analyses were those
who completed all sessions of neutral or expressive writ-
ing and completed at least baseline and immediate post
follow-up visits (N = 19 patients (11 = expressive writing,
8 = neutral writing), ten caregivers (6 = expressive writing,
4 = neutral writing). Participants were permitted to partici-
pate with or without providing cortisol samples; therefore
the sample size is reduced for the cortisol analyses (N = 16
patients, nine caregivers), with no significant differences
in willingness to provide cortisol samples observed be-
tween the two writing conditions.
Writing themes
A descriptive analysis was performed to determine the per-
centage of patients that chose each writing topic. Qualita-
tive review of the expressive writing condition essays using
established guidelines for content analysis of expressive
writing transcripts [15] resulted in a codebook with eight
topic categories, including family relationships, life-
threatening event, death, PD diagnosis, illness of a family
member, life review, self-health problems/illness, and reflec-
tion on the purpose of the expressive writing exercise.
Qualitative review of the neutral writing condition essays
was also performed as a manipulation check to ensure that
participants assigned to this condition did not write about
emotional topics despite instructions to write descriptively.
All neutral writing condition essays were judged by two re-
viewers and were determined to conform to study instruc-
tions; therefore, no further analyses were performed on the
neutral essays. Frequency analyses were performed to deter-
mine which codebook categories were used most frequently
by patients and caregivers. The largest percentage of the
participants focused on “Family Relationships” (36.4 %) as
their writing topic, followed by “Death” (25.5 %), “Life-
threatening Event” (12.7 %), and “Illness of a Family
Member” (9.1 %). Only 1.8 % of patients and caregivers in
the expressive writing condition wrote about the patient’s
PD diagnosis as their most stressful life experience.
Self-reported non-motor functioning
Overall, individuals with PD endorsed an average level of
eight non-motor symptoms (e.g., mood/anxiety symptoms,
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Table 1 Non-motor, cognitive, and physiological outcomes means, standard errors, and effects by writing condition and timepoint
Expressive writing Neutral writing
Outcome mean (SE) Pre Post 4 M 10 M Pre Post 4 M 10 M Effects F value p value η2
Self-reported non-motor functioning
MAQ 48.16
(2.35)
46.86
(2.03)
45.48
(2.14)
46.51
(1.99)
48.11
(2.48)
45.90
(2.15)
43.94
(2.26)
44.18
(2.10)
Time 3.65 .016* .13
Time X Condition .40 .75 .02
BDI-II 6.70
(1.46)
4.53
(.98)
5.99
(1.27)
6.03
(1.10)
6.20
(1.54)
4.66
(1.04)
4.65
(1.34)
5.03
(1.16)
Time 2.53 .064** .09
Time X Condition .45 .720 .02
AS 9.66
(1.12)
10.35
(1.25)
10.76
(1.27)
11.06
(1.37)
8.98
(1.18)
6.94
(1.32)
8.10
(1.34)
8.60
(1.44)
Time .76 .521 .03
Time X Condition 1.03 .383 .04
LASA 8.19
(.40)
8.63
(.36)
8.53
(.53)
7.89
(.52)
7.95
(.42)
8.31
(.38)
8.41
(.55)
7.68
(.55)
Time 2.01 .120 .07
Time X Condition .17 .916 .01
ECOG 66.03
(5.75)
57.97
(2.95)
61.05
(4.19)
57.88
(4.31)
51.63
(6.82)
48.81
(3.50)
48.94
(4.97)
51.31
(5.12)
Time 1.94 .132 .08
Time X Condition 1.02 .387 .04
PD-NMS (N = 19) 6.73
(1.34)
7.46
(1.04)
6.55
(1.35)
8.27
(1.35)
9.88
(1.57)
8.00
(1.22)
8.75
(1.59)
10.38
(1.58)
Time 2.02 .122 .11
Time X Condition .98 .408 .06
PDQ-39 (N = 19) 18.73
(5.16)
20.46
(5.47)
20.64
(4.70)
23.91
(5.40)
23.75
(6.06)
20.63
(4.42)
23.00
(5.51)
22.63
(6.33)
Time .55 .652 .03
Time X Condition .77 .516 .04
ZBI (N = 10) 7.20
(2.00)
5.20
(1.45)
7.40
(2.03)
7.00
(2.02)
7.40
(2.00)
4.40
(1.45)
4.20
(2.03)
4.80
(2.02)
Time 1.88 .160 .19
Time X Condition 1.00 .409 .11
Cognitive performance
Trails A 47.06
(2.88)
50.85
(2.91)
52.71
(2.49)
52.33
(3.23)
50.60
(2.82)
51.09
(2.84)
50.58
(2.43)
52.19
(3.16)
Time 1.52 .218 .06
Time X Condition .94 .426 .04
Trails B 51.64
(2.57)
54.25
(3.16)
54.74
(3.58)
52.03
(3.74)
51.14
(2.51)
51.85
(3.09)
54.95
(3.49)
57.13
(3.65)
Time 2.14 .102 .08
Time X Condition 2.14 .102 .08
ACT 46.42
(1.59)
47.91
(1.69)
48.23
(1.72)
48.63
(1.95)
44.75
(1.56)
47.76
(1.65)
46.58
(1.68)
48.20
(1.91)
Time 2.58 .060** .10
Time X Condition .56 .642 .02
DS 11.49
(.68)
10.69
(.69)
11.75
(.65)
11.99
(.63)
12.00
(.66)
12.36
(.68)
11.50
(.63)
11.78
(.62)
Time .28 .838 .01
Time X Condition 2.43 .072** .09
LNS (N = 18) 11.70
(.72)
12.27
(1.01)
11.88
(.73)
11.73
(.84)
8.70
(.95)
10.75
(1.35)
9.80
(.97)
9.35
(1.12)
Time 1.56 .214 .10
Time X Condition .48 .700 .03
CVLT-II
Trials 1–5 T 55.92
(3.84)
58.32
(3.33)
57.46
(3.62)
60.15
(3.38)
53.53
(3.75)
57.24
(3.25)
58.93
(3.54)
58.70
(3.30)
Time 2.86 .043* .11
Time X Condition .49 .691 .02
CVLT-II Short Delay
Free Recall
.17 (.36) .44 (.35) .48 (.45) .31 (.35) -.21
(.35)
.54 (.34) .38 (.44) .86 (.34) Time 3.54 .019* .13
Time X Condition 1.91 .135 .07
CVLT-II Long
Delay Free Recall
-.14
(.35)
.40 (.30) .28 (.41) .39 (.34) .10 (.34) .69 (.29) .51 (.40) .89 (.33) Time 5.76 .001* .19
Time X Condition .28 .841 .01
CVLT-II
Recognition
-.11
(.36)
.22 (.33) .38 (.37) .44 (.35) .23 (.35) .09 (.32) .54 (.36) .50 (.35) Time 2.58 .060** .10
Time X Condition .56 .642 .02
Salivary cortisol (μg/dL, values represent mean levels across 60 min post waking) Type III Tests of
Fixed Effects
F value p
Full sample (N = 25) .33 (.11) .29 (.11) .35 (.11) .40 (.11) .36 (.11) .54 (.12) .64 (.12) .65 (.13) Time 1.08 .366
Time X Condition .88 .456
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cognitive impairments, gastrointestinal problems, sleep dis-
turbances) consistent with prior research [7], non-clinically
significant levels of anxiety, depression, and apathy, and
positive QOL. Caregivers also reported non-clinical levels
of mental health symptoms, positive QOL, and low care-
giver burden. See Table 1 for means and standard errors at
baseline and across the four study timepoints. Repeated
measures analyses of variance (ANOVA) using a 2 Writing
Condition (traumatic, neutral) x 2 Participant Status (pa-
tient, caregiver) x 4 Timepoint (Baseline, Immediate Post,
4-Month, 10-Month) design were performed for each of
the self-reported outcomes to determine effects on non-
motor symptoms, overall and health-related QOL, anxiety,
depression, and caregiver burden. Given the assumption
that the unit of analysis for repeated measures ANOVA is
the subject and not the group, analyses were initially per-
formed with dyad status (coded as dyad or non-dyad) as an
additional between subjects variable to determine whether
participation in pairs affected the results. Dyad status did
not have a significant effect on any self-report outcomes
(results not included in this report); therefore, we pro-
ceeded with analyses on the mixed sample of dyadic and
non-dyadic caregivers and patients. Patients and caregivers
did not significantly differ in their self-reported anxiety, ap-
athy, overall QOL, or everyday cognitive functioning at
baseline; however, significant differences were detected in
depression, such that patients reported significantly higher
depression symptoms on the BDI-II at baseline than care-
givers, F(1,39) = 6.44, p = .015. Therefore, the total sample
of patients and caregivers was analyzed together for opti-
mal statistical power, but the effect of participant status
was included in all models to account for any differences
between the two samples. No baseline differences between
the expressive and neutral writing conditions were found.
No significant differences were detected between partici-
pants who handwrote compared to those who wrote on a
computer; therefore, analyses were performed on the com-
bined sample.
See Table 1 for means and standard errors separated
by writing condition across the four study time points.
Appropriate F values, significance levels, and effect sizes
for the main effect of time and interaction of time and
writing condition are also included in Table 1. Signifi-
cant and marginally significant effects are highlighted
below. The effect size value partial eta squared (η2) cap-
tures the proportion of variance accounted for by each
effect (e.g., .31 = 31 %). Interpretation of η2 effect sizes
should be as follows: ≥ .02 = small effect, ≥ .13 =medium
effect, ≥ .26 = large effect.
Anxiety symptoms (MAQ) significantly declined follow-
ing the intervention, F(3, 75) = 3.65, p = .016, η2 = .13, with
no significant differences between the two writing groups.
Depression symptoms (BDI-II) showed a marginally sig-
nificant trend for decreasing over time in both writing
conditions, F(3, 75) = 2.53, p = .064, η2 = .09, with a signifi-
cant reduction from baseline to immediate post-test,
F(1,25) = 5.57, p = .026, η2 = .18. The overall effects of
Timepoint and the interaction of Timepoint X Condition
were not significant for self-reported everyday cognitive
functioning (ECOG); however, a significant Timepoint X
Condition interaction was observed from the 4-Month to
the 10-Month follow up, with improvement in cognitive
functioning for expressive writers and the opposite pattern
for neutral writers, F(1, 24) = 7.51, p = .011, η2 = .24.
Within the caregiver sample, caregiver burden (ZBI) did
not show the anticipated main effect of time or interaction
of time and writing condition, but there was a marginally
significant quadratic trend, F(1,8) = 4.49, p = .067, η2 = .36,
with a significant reduction in burden from baseline to
immediate post, F(1, 8) = 5.95, p = .041, η2 = .43. No sig-
nificant or marginally significant effects of Writing Condi-
tion, Participant Status, or Timepoint were observed on
other self-report outcome measures, which included
PD-related QOL (PDQ-39), non-motor symptoms (PD-
NMS), apathy symptoms (Apathy Scale), and overall
QOL (LASA), all ps >.10.
Table 1 Non-motor, cognitive, and physiological outcomes means, standard errors, and effects by writing condition and timepoint
(Continued)
Time X Condition X
Status
2.78 .049*
Patients (N = 16) .28 (.12) .23 (.12) .32 (.13) .29 (.12) .37 (.13) .73 (.13) .43 (.14) .63 (.15) Time 1.31 .288
Time X Condition 2.62 .067**
Caregivers, (N= 9) .38 (.20) .34 (.20) .37 (.20) .50 (.20) .34 (.20) .35 (.20) .84 (.22) .66 (.22) Time 1.34 .287
Time X Condition 1.24 .319
N = 29 for all analyses unless otherwise specified
Alpha level is designated as *p <.05, and **p <.10 designates a marginally significant trend
η2 = proportion of variance accounted for by each effect (e.g., .31 = 31 %)
Interpretation of η2 effect sizes should be as follows: ≥ .02 = small effect, ≥ .13 =medium effect, ≥ .26 = large effect
Outcome abbreviations are as follows: MAQ multidimensional anxiety questionnaire, BDI-II Beck Depression Inventory-II, AS apathy scale, LASA linear analogue self
assessment, ECOG everyday cognition scale, PD-NMS Parkinson’s disease non-motor symptom questionnaire, PDQ-39 Parkinson’s disease quality of life-39, ZBI Zarit
Burden inventory, ACT auditory consonant trigrams, DS digit span, LNS letter number sequencing, CVLT-II California verbal learning test-II, CAR cortisol
awakening response
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Cognitive functioning
Baseline cognitive functioning did not differ significantly
between caregivers and patients on main cognitive out-
come measures; therefore repeated measures ANOVAs
were performed on the combined sample to assess the ef-
fects of Participant Status, study Timepoint, and Writing
Condition on cognitive outcomes with optimal statistical
power. No baseline differences between the expressive and
neutral writing conditions were found. As noted above,
dyad status was evaluated as a potential factor that could
have affected the repeated measures ANOVA results, but
no significant effects of dyad status were found on cogni-
tive outcomes (results not included in this report).
Performance on tasks of verbal learning (CVLT Trials
1–5), F(3,72) = 2.86, p = .043, η2 = .11 and memory
(CVLT Short Delay Free Recall), F(3, 72) = 3.54, p = .019,
η2 = .13; (CVLT Long Delay Free Recall), F(3, 72) = 5.76,
p = .001, η2 = .19 significantly improved over time, but
no differences were found between the two writing con-
ditions. No significant changes were found in partici-
pants’ performance on tasks measuring processing speed
(Trails A), processing speed and mental flexibility (Audi-
tory Consonant Trigrams and Trails B), and auditory at-
tention and working memory (Digit Span). A marginally
significant effect of Timepoint was found on a mental
flexibility task (ACT) such that performance improved
over time in both writing groups, F(3,72) = 2.58, p = .060,
η2 = .10. Finally, a marginally significant interaction of
Timepoint and Writing Condition was seen on a test of
auditory attention and working memory (Digit Span),
with slight overall improvement seen for those in the ex-
pressive writing condition compared to the neutral writ-
ing condition, F(3,72) = 2.43, p = .072, η2 = .09.
Cortisol awakening response
Sample collection time logs revealed participants were
compliant with salivary collection procedures. Multilevel
modeling was used to analyze the fixed effects of Writ-
ing Condition and Participant Status and random effects
of study Timepoint on the CAR. No baseline differences
between the expressive and neutral writing conditions or
between patients and caregivers were found. Dyad status
was initially included in the model as an additional fixed
effect to determine whether those participating in pairs
differed in their cortisol response compared to those
participating alone. No significant effect of dyad status
was found (results not included in this report).
A significant three-way interaction of Participant Sta-
tus x Condition X Timepoint, F(3, 52.94) = 2.78, p = .049,
was observed. When evaluated separately for patients
and caregivers, the interaction of Condition X Time-
point trended towards significance for patients, F(3,
33.58) = 2.62, p = .067, but not for caregivers, p = .319.
CAR was lower for individuals with PD in the expressive
writing condition at immediate-post and 10-month follow-
up compared to those in the neutral writing condition.
Discussion
This study is the first to examine the feasibility and po-
tential benefits of an expressive writing intervention for
individuals with PD and their caregivers. Attrition rates,
a variety of self-report outcomes, performance on tests
of neurocognitive functioning, and an objective stress
hormone response measure were assessed to determine
the feasibility and effect size of an expressive writing
intervention in PD patient and caregiver samples.
Although some positive findings were observed, the
majority of outcome variables were non-significant. In a
pilot study, small sample size can often limit conclusions
that can be made. While the positive results are encour-
aging, experience of significant study recruitment and
retention issues were challenging. Specifically, nearly
one third of consented participants failed to complete
the study protocol. The majority of these individuals
were lost to follow up and failed to return multiple con-
tact attempts by study personnel. Of those who provided
a reason for discontinuing, travel distance, hesitation to
engage in personal disclosure, and the emergence of new
medical symptoms unrelated to study participation were
reported. Most participants agreed to provide salivary
cortisol samples, but a small number chose not to do so.
Attrition rates and willingness to provide salivary corti-
sol samples did not differ systematically between expres-
sive and neutral writing conditions.
Overall, these results indicate that a brief expressive
writing intervention and collection of salivary samples was
tolerated by most participants and that study condition
did not influence willingness to participate in the study.
These findings suggest that a larger scale trial would likely
be successful in recruiting and retaining a sufficient sam-
ple, but that additional efforts may be needed to reduce at-
trition to recruit necessary numbers of participants in a
reasonable timeframe. The length of follow up and at
home collection of cortisol samples in this study may have
been burdensome to participants. Future studies might in-
clude fewer follow up visits, particularly given that most
effects of the intervention were detected at immediately
post intervention. Collection of cortisol samples immedi-
ately before and after writing to detect state-level shifts in
cortisol reactivity might reduce participant burden and
provide additional insight into the physiological effects of
expressive writing.
Another unanticipated finding of this pilot study in-
cluded that most of the participants, including both pa-
tients and caregivers, did not choose a PD-related topic for
their expressive writing. The most frequently chosen topics
involved themes such as family relationships, death, and
life-threatening events. This finding suggests that in this
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sample the most stressful factors in the patients’ and care-
givers’ lives were not PD-related and tend to be common
life events that are not particularly focused on PD. Aware-
ness that general life stressors and their impact on individ-
uals with PD and their caregivers may be of more concern
than PD-specific issues is critical for health care providers
as well as the general public to recognize when helping
support and provide care for individuals with PD and their
caregivers. It remains unclear if common life stressors have
additional impacts on individuals’ motor and non-motor
symptoms, but this certainly seems plausible. Consider-
ation of potential impact of common life stressors on emo-
tional and physical health is recommended to provide
individuals with PD and their caregivers more effective, ef-
ficient and comprehensive treatment plans.
Importantly, in the evaluation of self-reported out-
comes, results showed positive changes over time on
measures of anxiety, depression, and caregiver burden in
both the expressive and neutral writing conditions. Im-
provement of emotional functioning in a neurodegenera-
tive disease with known impact on dopamine levels
demonstrates potential promise of biopsychosocial inter-
ventions in this population. Superior improvement seen
within the expressive writing condition on a measure of
self-reported everyday cognitive functioning is also en-
couraging but should be replicated, given that improve-
ments were only observed during the follow up period.
No reliable changes were observed on measures of apathy,
PD-related or overall QOL, or non-motor symptoms. One
explanation for the lack of change on these measures
could be the low levels of apathy and non-motor symp-
toms and high QOL reported within this sample.
Indeed, prior research confirms that individuals with
mild to moderate distress at baseline are most likely to
benefit from expressive writing [34]. Less robust benefit
from the intervention observed in our sample may have
been due to the non-clinical levels of emotional symptoms
reported by participants. In addition, improvements took
place in both writing conditions, suggesting that involve-
ment in a research study and perhaps especially engage-
ment in writing about both emotional and neutral topics
may serve as a buffer against the progression of emotional
symptoms in individuals with PD and their caregivers.
Several previous studies have shown a lack of difference in
outcomes across writing conditions in caregivers [33, 43]
and patient [42] samples, particularly on psychological
health outcomes. While the reasons for these discrepant
findings remain unclear, our results suggest that a brief,
psychosocial intervention has benefits on select emotional
outcomes for individuals with PD and their caregivers.
With regard to cognitive functioning, verbal learning
and memory improvements were observed independent
of writing condition. This finding is not likely due to prac-
tice effects given use of alternate forms and largest impact
of repeated exposure to cognitive tasks between the first
and second exposure [26]. Learning and memory retrieval
problems are commonly observed in individuals with PD
and persons experiencing significant life stressors [51]. Ex-
perience of these symptoms can have negative impact on
work functioning and independent living. Cognitive re-
habilitation techniques have increasingly been studied in
individuals suffering from Mild Cognitive Impairment
(MCI), with mixed but some promising results [20, 25],
but have not yet been explored in individuals with PD. We
are currently completing two trials examining in-person
and computerized cognitive rehabilitation strategies in in-
dividuals with PD-MCI and initial results show some
positive impact [29, 30]. Further study of behavioral treat-
ments for memory issues is relevant for both medical and
healthy populations given the aging of our population.
These findings highlight the possibility that emotional and
cognitive functioning may interact in both individuals with
PD and their caregivers.
Results examining the effects of the writing conditions
and participant status over time on the CAR were also en-
couraging. The hypothesis that expressive writing would
lead to lower CAR over the course of the study was par-
tially supported among individuals with PD. However,
caregiver participants did not show the expected decline
in CAR. In patients, the pattern of change in CAR over
time was indicative of increased CAR for those in the neu-
tral writing condition, with a more stable trajectory for
those in the expressive writing condition. This pattern
suggests a possible buffer effect of expressive writing com-
pared to neutral writing on rising cortisol levels in individ-
uals with PD. It is also important to note that, although
there was a significant interaction of participant status,
writing condition, and time, the effect was trending to-
wards significance but did not reach significance when ex-
amined within the patient sample.
Limitations
These findings should be interpreted in the context of
several study limitations. The sample size was somewhat
low, although not substantially lower than other pilot
studies of expressive writing in other chronically ill pop-
ulations [9, 42]. Low sample size limits statistical power
and the ability to detect statistically significant effects.
However, the fact that we were able to detect several sig-
nificant effects, even in our limited sample size, speaks to
the potential efficacy of this intervention. A second limita-
tion is that several of our measures have not been previ-
ously used in individuals with PD or among caregivers. As
such, interpretation of the MAQ and CAR results were
guided by literature on related samples and should be rep-
licated in future research. In addition, we did not control
for medication usage, including dosage amounts of levo-
dopa medication commonly used to treat PD and steroid
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medications, which may have influenced cortisol findings.
Finally, our sample was fairly homogenous in terms of ra-
cial/ethnic background, educational attainment, and func-
tional status, and results may not generalize to more
diverse or more impaired groups of PD patients and care-
givers. Inclusion of a wider variety of individuals should
be prioritized in future studies to determine whether writ-
ing interventions are useful to PD patients and caregivers
from different backgrounds and with more significant
functional impairments.
Conclusions
This pilot study provides initial findings regarding the
feasibility and effectiveness of a brief, cost-effective psy-
chosocial intervention among individuals with PD and
their caregivers. The study demonstrated moderate feasi-
bility but questionable effectiveness for expressive writ-
ing in a small PD patient and caregiver sample. No
significant differences between the expressive and neu-
tral writing conditions were found on emotional and
cognitive outcome variables. However, positive changes
over time on measures of anxiety, depression, and care-
giver burden were observed in both the expressive and
neutral writing conditions, verbal learning and memory
improvements were observed independent of writing
condition, and the hypothesis that expressive writing
would lead to lower CAR over the course of the study
was supported, but only among individuals with PD.
Low recruitment rates (40.9 % of eligible participants
chose to participate) and fairly high attrition rates (29.3 %
of all participants dropped out before study completion)
were challenges encountered in this study. Individuals who
declined participation cited travel distance or lack of inter-
est as primary reasons for not completing the study, sug-
gesting that telehealth or internet-based protocols for
expressive writing may increase recruitment rates. Attrition
rates were largely explained by changes in participants’ life
circumstances, whether related to the emergence of new
medical symptoms unrelated to the study or other life obli-
gations that prevented travel to the clinic to complete the
study. Given the older age of our targeted sample, it is not
surprising that new medical problems were a barrier to
completing the study. As with recruitment challenges, one
solution to the barrier of traveling to our clinic is to offer
telehealth or internet-based protocols for future interven-
tions. A final consideration is that, as acknowledged in our
informed consent process with participants, writing about
an emotionally stressful life experience can result in a tem-
porary increase in negative emotions and physiological
arousal (typically followed by a larger decrease in these
symptoms). As such, some participants or potential partici-
pants may have declined to participate or dropped out of
the study to avoid this temporary discomfort, leading to re-
duced recruitment rates and/or increased attrition.
Changes that occurred in our sample may be attributable
to the passage of time and/or the process of writing,
whether about a neutral or an emotionally salient topic,
which is consistent with some prior expressive writing
studies, which also did not detect differences between the
writing conditions [36]. Expressive writing was compared
to neutral writing in order to be consistent with prior re-
search, based on the assumption that writing about an
emotional topic promotes therapeutic change [45], while
writing about a neutral topic has not been theorized to
promote clinically meaningful changes. However, a no-
writing control group may be a useful addition in future
studies in order to better control for potential confounds
(e.g., maturation) as well as potential benefits associated
with the writing process itself.
One exception to the pattern of null results in our study
was the three-way interaction of participant status, writing
condition, and time on the CAR, with lower cortisol re-
activity seen for PD patients across time in the expressive
writing condition. However, these results are tentative
given the small sample and the lack of significant effects
within the PD sample. It may be that three sessions of
emotional writing were not sufficient to produce statisti-
cally reliable and clinically significant change in cortisol
reactivity and psychological distress for individuals with
PD and their caregivers. It is possible that additional writ-
ing sessions would be necessary to produce more marked
changes in this population, given the complexity of motor
and non-motor symptoms in PD.
Future work in this area should explore the specific con-
ditions of writing that can enhance its benefits, especially
among individuals with PD and other movement disorders
and their caregivers, for whom very few empirically evalu-
ated alternative and complementary interventions are cur-
rently available. Further qualitative examination of patients’
and caregivers’ written narratives is planned and will facili-
tate a test of theories of expressive writing as well as gener-
ate new explanations for its mechanisms of action within a
novel population. In sum, this study is an important first
step towards empirical evaluation of a well-established psy-
chosocial intervention within an underserved population,
and ongoing efforts of this kind are likely to substantially
contribute to the physical and emotional well-being of in-
dividuals with PD and their caregivers.
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